Indeed, residual invasive disease is the most significant adverse prognostic factor for DFS and overall survival (OS) in HER2+ breast cancer [9,10,11,12]; thus, it is important to identify these patients and escalate systemic therapy, as described in Recommendation 8. This evidence concerns the gene ERBB2 and breast carcinoma.